

Supporting Information

Ensemble-based Virtual Screening Reveals Novel Antiviral Compounds for Avian Influenza
Neuraminidase

*Lily S. Cheng, Rommie E. Amaro, Dong Xu, Wilfred W. Li, Peter W. Arzberger, and J. Andrew
McCammon*

Table of Contents:

Supporting Figures – S2

Supporting Tables – S7




Figure S1. The successful re-docking of Tamiflu to the holo crystal structure (2HU4) is shown. The crystallized position of Tamiflu is shown in black without hydrogens. The docked position of Tamiflu is shown colored by atom type with polar hydrogens added. The docked pose agrees closely with the crystal pose, with minor deviations.




Figure S2. The molecular surface of the apo crystal structure with selected hits docked illustrates the position of (A) the sialic acid cavity, (B) the 150-cavity, and (C) the 430-cavity. Two hits that span the 150- and 430-cavities are also shown (D). Electrostatic surface potential scale shown in panel D.




Figure S3. Four hits that bind in the sialic acid cavity are shown, each docked to the structure to which they exhibit the best binding affinity. (C) NSC117079 simultaneously docks in the sialic acid cavity and in the adjacent open 430-cavity.




Figure S4. Six hits that bind in the 150-cavity and/or the 430-lcavity are shown, each docked to the structure to which they exhibit the best binding affinity. (A) NSC45583, (B) NSC18312, and (D) NSC17245 bind in the open or wide-open 150-cavity. (C) NSC106920 and NSC327704 bind in the open and closed 430-cavity, respectively. (F) NSC37245 is a compound that binds across the 150- and 430-cavities.

Table S1. Top hits to the receptor active site (sialic acid binding site)

Ligand	Apo Crystal	Apo-1	Apo-2	Apo-3	Holo Crystal	Holo-1	Holo 2	Holo-3
211332	-7.99 (63)	-9.74 (94)	-8.91 (100)	-11.6 (100)	-9.96 (100)	-10.89 (74)	-9.96 (100)	-9.35 (98)
109836	-9.83 (31)	-9.50 (19)	-8.99 (18)	-9.92 (17)	-11.14 (43)	-9.17 (12)	-10.41 (22)	-9.89 (32)
Oseltamivir	-7.91 (14)	-7.22 (28)	-7.82 (39)	-7.88 (28)	-10.20 (43)	-10.24 (53)	-10.06 (60)	-8.57 (41)
<u>350191</u>	-7.54 (8)	-8.24 (15)	-6.89 (20)	-8.70 (20)	-8.52 (26)	-10.0 (34)	-8.73 (35)	-6.79 (33)
<u>117079</u>	-8.29 (11)	-10.6 (22)	-9.81 (25)	-9.99 (10)	-7.99 (11)	-9.17 (7)	-10.89 (7)	-9.29 (6)
Zanamivir	-7.93 (12)	-6.71 (6)	-5.49 (8)	-8.35 (6)	-9.79 (29)	-9.41 (26)	-8.45 (23)	-6.66 (7)
<u>141562</u>	-6.98 (35)	-8.23 (52)	-8.90 (77)	-9.05 (32)	-8.28 (20)	-9.71 (46)	-7.81 (29)	-7.77 (23)
<u>5069</u>	-8.35 (30)	-7.31 (25)	-9.60 (63)	-6.39 (18)	-8.60 (28)	-7.21 (39)	-8.97 (25)	-7.50 (29)
131612	-9.54 (34)	-8.05 (10)	-8.11 (30)	-7.90 (15)	-9.31 (29)	-8.36 (19)	-9.33 (32)	-8.09 (49)
<u>70194</u>	-7.55 (29)	-8.73 (36)	-9.43 (50)	-7.97 (26)	-6.40 (18)	-7.61 (19)	-7.86 (41)	-7.36 (34)
135371	-7.28 (27)	-7.81 (16)	-6.65 (25)	-8.69 (66)	-9.24 (62)	-8.22 (48)	-8.15 (22)	-7.77 (20)
<u>164640</u>	-6.60 (16)	-7.42 (12)	-7.04 (19)	-8.21 (24)	-8.66 (25)	-8.69 (21)	-7.38 (30)	-9.06 (34)
Peramivir	-6.11 (23)	-5.09 (18)	-5.77 (16)	-7.81 (15)	-9.00 (16)	-8.08 (17)	-7.04 (9)	-6.98 (10)
SA	-7.54 (9)	-6.86 (7)	-7.31 (11)	-7.98 (9)	-7.89 (18)	-7.35 (11)	-7.96 (25)	-7.93 (13)
DANA	-6.77 (9)	-6.66 (19)	-6.86 (9)	-7.15 (12)	-7.85 (12)	-7.00 (11)	-7.69 (15)	-7.77 (20)

Top hits are shown sorted by lowest binding energy. Each compound is identified by its NSC classification number. Known inhibitors are included for reference. The table expresses the binding affinity of each ligand as the Gibbs free energy (kcal/mol) of the most populated cluster followed by the percentage of docked conformations with that energy in parenthesis. Bold font denotes that the compound is among the top 30 lowest energy hits for the given receptor. Gray font denotes that the clustering of the docking did not meet the 25 percent cutoff. Compounds identified from the ensemble screens that were not identified by the crystal structure screens are underlined.

Table S2. Top hits to other locales in the receptor binding site.

Ligand	Apo Crystal	Apo-1	Apo-2	Apo-3	Holo Crystal	Holo-1	Holo 2	Holo-3
46080	-10.60 (35)	-6.34 (8)	-8.98 (40)	-7.98 (13)	-10.35 (29)	-8.70 (23)	-7.56 (14)	-7.24 (14)
45583	-10.57 (32)	-10.24 (25)	-9.36 (18)	-8.46 (19)	-9.57 (14)	-9.55 (34)	-9.95 (37)	-10.53 (13)
<u>18312</u>	-8.49 (47)	-10.56 (63)	-8.29 (76)	-7.44 (50)	-7.79 (29)	-7.43 (49)	-7.88 (49)	-7.48 (30)
<u>106920</u>	-8.62 (10)	-7.03 (11)	-9.13 (19)	-10.08 (45)	-8.80 (11)	-7.83 (18)	-9.32 (34)	-8.02 (9)
17245	-10.07 (33)	-9.60 (33)	-9.76 (20)	-8.34 (13)	-8.83 (8)	-9.53 (16)	-9.58 (11)	-8.15 (8)
45576	-9.79 (29)	-10.05 (54)	-9.20 (42)	-9.00 (20)	-7.63 (13)	-7.43 (20)	-8.33 (18)	-8.12 (26)
327704	-9.52 (27)	-8.52 (28)	-9.75 (69)	-9.01 (66)	-9.97 (48)	-8.96 (84)	-8.39 (64)	-7.98 (38)
37245	-9.80 (28)	-7.20 (8)	-7.47 (7)	-7.98 (17)	-7.83 (24)	-8.31 (11)	-8.84 (14)	-7.20 (5)
<u>59620</u>	-8.41 (72)	-9.79 (60)	-8.18 (52)	-7.45 (62)	-7.88 (70)	-7.87 (34)	-8.25 (51)	-7.33 (69)
<u>16163</u>	-7.15 (12)	-9.72 (28)	-8.45 (14)	-7.23 (10)	-7.06 (26)	-5.79 (9)	-6.25 (26)	-7.16 (15)
90630	-7.53 (25)	-7.92 (19)	-8.56 (36)	-8.33 (14)	-7.86 (16)	-7.27 (22)	-9.71 (42)	-7.74 (14)
<u>148354</u>	-7.95 (11)	-8.78 (7)	-8.48 (9)	-9.49 (23)	-8.15 (7)	-7.82 (11)	-9.70 (29)	-8.73 (22)
327705	-9.53 (36)	-7.32 (17)	-8.82 (26)	-8.37 (37)	-9.76 (24)	-9.30 (44)	-9.39 (30)	-7.69 (15)
<u>372294</u>	-8.09 (12)	-7.17 (22)	-8.86 (7)	-9.45 (31)	-9.02 (17)	-8.36 (21)	-7.54 (36)	-8.01 (17)
<u>45582</u>	-7.44 (8)	-8.03 (9)	-9.37 (28)	-8.27 (9)	-7.62 (10)	-8.50 (17)	-7.44 (9)	-7.79 (14)
371688	-7.87 (22)	-8.94 (21)	-8.94 (17)	-7.74 (18)	-9.35 (26)	-8.71 (19)	-7.72 (10)	-7.28 (14)
<u>72254</u>	-8.30 (13)	-8.59 (41)	-9.25 (25)	-8.48 (37)	-8.76 (14)	-8.43 (17)	-8.61 (28)	-7.88 (17)

Same annotation used as Table S1.

Table 3. Top hits re-ranked by RCS

Ligand	W.H. RC Mean	W.A. RC Mean	RC STD	RC Mean	RC Min.	E. Mean	E. Min.	IUPAC Name
109836	-10.63	-10.42	0.55	-10.00	-11.08	-9.82	-10.41	1-(3-((3-(hydroxy(oxido)amino)benzyl)oxy)phenyl)-4,6-diimino-2,2-dimethyl-1,3,5-triazinane
211332	-10.34	-10.13	0.55	-10.05	-12.34	-10.07	-10.89	2,4-diaminohexahydro-5-pyrimidinecarbonitrile
45583	-10.09	-9.78	0.86	-9.09	-10.58	-10.01	-10.53	3-hydroxy-4-(1-naphthyl diazenyl)-2,7-naphthalenedisulfonic acid
Oseltamivir	-9.82	-9.60	0.66	-9.05	-10.63	-9.62	-10.24	(3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylic acid
Zanamivir	-9.38	-8.89	0.92	-8.00	-10.22	-8.17	-9.41	(4S,5R,6R)-5-acetamido-4-(diaminomethylideneamino)-6-[(1R,2R)-1,2,3-trihydroxypropyl]-5,6-dihydro-4H-pyran-2-carboxylic acid
<u>106920</u>	-9.20	-8.82	0.77	-7.11	-10.23	-8.39	-9.32	N/A
17245	-9.18	-8.92	0.57	-8.64	-9.74	-9.09	-9.58	11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl cyclopentanecarboxylate
<u>350191</u>	-9.14	-8.80	0.70	-8.36	-10.29	-8.51	-10.00	S-(2,4-diaminobutyl) dihydrogen thiophosphate
<u>148354</u>	-9.12	-8.74	0.90	-8.00	-9.62	-8.75	-9.70	8-hydroxy-7-(1-naphthyl diazenyl)-5-quinolinesulfonic acid
131612	-9.10	-8.82	0.60	-8.44	-10.00	-8.59	-9.33	2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(4-hydroxy-3-(hydroxy(oxido)amino)phenyl)propanoic acid
37245	-9.02	-8.61	0.90	-8.34	-9.61	-8.12	-8.84	1,4-bis(2-naphthylsulfonyl)piperazine
<u>45582</u>	-9.00	-8.45	0.78	-8.07	-9.77	-7.91	-8.50	7-hydroxy-8-(1-naphthyl diazenyl)-1,3-naphthalenedisulfonic acid
90630	-8.89	-7.97	0.97	-7.70	-9.73	-8.24	-9.71	1-dibenzo[b,d]furan-3-yl-2-(2-piperidinyl)ethanol
<u>5069</u>	-8.83	-8.73	0.36	-8.31	-9.85	-7.89	-8.97	4-nitro-2,3-dioxo-2,3-dihydro-9,10-secostrychnidin-10-oic acid
327705	-8.83	-8.59	0.62	-8.27	-9.44	-8.79	-9.39	2-chloro-3-phenanthro[9,10-e][1,2,4]triazin-3-ylsulfanyl naphthalene-1,4-dione
<u>141562</u>	-8.78	-8.12	1.08	-8.44	-10.65	-8.43	-9.71	1-((2-methyl-3-quinoliny)methyl)-1(λ)5,3,5,7-tetraazatricyclo [3.3.1.1~3,7~] decane
<u>117079</u>	-8.72	-7.90	0.78	-8.67	-10.41	-9.78	-10.89	1-amino-4-(3-(aminosulfonyl)anilino)-9,10-dioxo-9,10-dihydro-2-anthracenesulfonic acid
327704	-8.60	-8.29	0.70	-7.86	-10.04	-8.44	-8.96	(phenanthro[9,10-e][1,2,4]triazin-3-ylthio)acetic acid
<u>72254</u>	-8.47	-8.17	0.64	-8.13	-9.40	-8.31	-8.61	2-hydroxy-2-((3-oxoestr-4-en-17-yl)oxy)-1H-indene-1,3(2H)-dione
<u>164640</u>	-8.37	-8.14	0.59	-8.05	-9.54	-8.38	-9.06	2-(4-chloro-2-methylphenoxy)-N-(4,6-diamino-1,3,5-triazin-2-yl)acetamide
135371	-8.28	-8.05	0.51	-7.87	-9.80	-8.05	-8.22	N/A
45576	-8.20	-8.16	0.21	-8.33	-9.32	-7.96	-8.33	5-((2-hydroxy-1-naphthyl) diazenyl)-2-naphthalenesulfonic acid
46080	-8.05	-7.43	0.93	-7.02	-9.92	-7.83	-8.70	N-(7-chloro-4-hydroxy-5-phenyl-3H-1,4(λ)5-benzodiazepin-2-yl)-N-methyl-beta-alanine
<u>372294</u>	-7.92	-7.81	0.35	-7.86	-9.32	-7.97	-8.36	(phenanthro[9,10-e][1,2,4]triazin-3-ylthio)acetic acid

<u>59620</u>	-7.85	-7.55	0.53	-7.76	-9.42	-7.82	-8.25	4a,6a,9-trimethyl-6,7-dioxo-2,3,4,4a,4b,5,6,6a,6b,7,10,10a,11,11a,11b,12,13,13a-octadecahydro-1H-indeno[2,1-a]phenanthren-2-yl acetate
Peramivir	-7.79	-7.43	0.80	-6.99	-8.74	-7.37	-8.08	(1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylidene-amino)-2-hydroxycyclopentane-1-carboxylic acid trihydrate
<u>70194</u>	-7.74	-7.62	0.38	-8.00	-9.92	-7.61	-7.86	N/A
<u>18312</u>	-7.72	-7.69	0.18	-7.66	-9.88	-7.60	-7.88	3-hydroxyestra-1,3,5(10)-trien-17-yl dihydrogen phosphate
SA	-7.47	-7.32	0.42	-7.37	-9.04	-7.75	-7.96	N-acetylneuraminic acid
371688	-7.44	-7.18	0.37	-7.53	-9.21	-7.90	-8.71	7-methoxy-3-(7-methoxy-4,5-dihydrobenzo[g][1,2]benzoxazol-3-yl)-4,5-dihydrobenzo[g][1,2]benzoxazole
DANA	-7.41	-7.27	0.45	-7.11	-8.54	-7.49	-7.77	(4S,5R,6R)-5-acetamido-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]-5,6-dihydro-4H-pyran-2-carboxylic acid
<u>16163</u>	-7.07	-6.56	0.65	-6.84	-8.28	-6.40	-7.16	((1-amino-6-sulfo-2-naphthyl)oxy)acetic acid

The 27 top hits are listed in the table above, re-ranked by their weighted harmonic RC mean. The columns are binding energies in kcal/mol in the following order: weighted harmonic RC mean (WH RC mean), weighted arithmetic mean (WA RC mean), RC standard deviation (RC std), RC mean, RC minimum (RC min.), Ensemble mean (E mean), and Ensemble minimum (E. min.).